Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 65/100

RAD Presentation June 2026

Friday, June 5, 2026 1 min read
Key Takeaway: Radiopharm Theranostics has made significant progress with the dosing of its first patient in the Phase 1/2a clinical study of BetaBart (RV-01). Additionally, the company has received IND approval from the US FDA to initiate a therapeutic clinical study targeting B7H3. The company has also provided positive updates across its four clinical programs.
Price reaction · baseline $4.63 (2026-06-04 close) · hit pre-market · clean, no other RADX news in the window
day 0 close
-6.7%
day 1 · peak
-9.1%
day 3
-6.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics has initiated a Phase 1/2a clinical study.
  • Positive clinical updates have been provided across four programs.
  • Dr. Oliver Sartor has joined the Scientific Advisory Board.

Full Press Release Details

• Investor Presentations
• June 5, 2026
Loading Viewer…

More Announcements & Updates

• Announcements
• July 31, 2023
• Announcements
• November 16, 2022
• Announcements
• April 28, 2023
• Announcements
• September 28, 2023

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the latest update from Radiopharm Theranostics?

Radiopharm Theranostics has dosed its first patient in the Phase 1/2a clinical study of BetaBart.

Who joined the Scientific Advisory Board of Radiopharm?

Dr. Oliver Sartor has been appointed to the Scientific Advisory Board.

What FDA approval did Radiopharm receive?

Radiopharm received IND approval to initiate a Phase I therapeutic clinical study targeting B7H3.

When was the investor presentation scheduled?

The investor presentation is scheduled for June 5, 2026.

Tags: RADX Viatris Investor Conferences Healthcare BetaBart Phase 1/2a clinical study FDA approval
Last updated: Jun 5, 2026